Drug class
Cereblon E3 ligase modulator (CELMoD); immunomodulatory antineoplastic small molecule
Mechanism of action
Binds cereblon, the substrate receptor of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and degradation of transcription factors including Ikaros (IKZF1) and Aiolos (IKZF3). This alters myeloma-cell survival and immune-cell function.
General use cases
- In combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent under the US FDA ZENBEXUS indication (approved 13 August 2026)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
